Guadecitabine (SGI-110) Offers Potential New Treatment Option for Myelodysplastic Syndromes, Phase 2 Study Finds
Stella Richards Keywords 1. Guadecitabine 2. Myelodysplastic Syndromes Treatment 3. Hypomethylating Agents 4. Phase 2 Clinical Trial…
Read MoreHypomethylating Agents
Favorable Outcomes With Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Higher Risk Myelodysplastic Syndrome Patients
DOI: 10.1016/j.clml.2019.03.016 Abstract A groundbreaking study has recently brought forth optimistic findings for patients with…
Read More